Trellus Health plc
("Trellus Health" or the "Company")
Posting of Annual Report &
Accounts
and
Notice of Annual General Meeting
LONDON, UK.
AND NEW YORK, U.S. (20 May 2024). Trellus
Health plc (AIM: TRLS), a health services company delivering
innovative, scientifically validated programs and technologies
designed to facilitate the management of chronic conditions,
improve health outcomes and lower the costs of care, confirms that
the Annual Report and Accounts for the year ended 31 December 2023
("2023 Annual Report") and the Notice of the 2023 Annual General
Meeting ("AGM") have now been published on the Company's
website here.
The 2023 Annual Report, the Notice of AGM
and details for voting by proxy will be posted to shareholders
today, on 20 May 2024.
The AGM will be held at 12pm on 14 June 2024 at
the offices of Shoosmiths, at 1 Bow Churchyard, London EC4M 9DQ,
and will consider the Resolutions set out in the Notice of
AGM.
Proxy
voting
Shareholders will not receive a hard copy form
of proxy for the 2024 AGM in the post. Instead, you will be able to
vote electronically using the Link Investor Centre app or at
https://investorcentre.linkgroup.co.uk/Login/Login.
Proxy votes must be received no later than 12pm on 12 June
2024.
Shareholders may request a hard copy form of
proxy directly from the Registrars, Link Group, on Tel: 0371 664
0300. Calls are charged at the standard geographic rate and will
vary by provider. Calls outside the United Kingdom will be charged
at the applicable international rate. Lines are open between 09:00
- 17:30, Monday to Friday excluding public holidays in England and
Wales.
For further
information please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, CEO and
Co-Founder
|
Via Walbrook
PR
|
|
Dr. Daniel Mahony,
Chairman
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Aubrey Powell / Jen
Boorer
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Sam Allen / Phillip
Marriage
|
Mob: +44 (0)7980 541
893 / 07748 651 727 / 07867 984 082
|
|
|
| |
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a
health services company providing value-based innovative solutions
and services for chronic condition management that prioritises
improved outcomes and member experiences while managing costs of
care.
Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their
physical and emotional health. Trellus Elevate's™ clinically proven
solutions result in relieving disease burden, building
self-management skills and promoting positive health behaviours
that improve outcomes and enables thriving in the face of a chronic
condition.
The Company's proven whole person
approach recognises the interconnectedness of various aspects of a
person's life and aims to address the whole spectrum of factors
that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care.
Trellus Health's approach enables better health outcomes in a
member-centric, personalised and comprehensive holistic
solution.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both experts at treating and healing both the physical and
emotional impacts of IBD and have been innovators for whole-person
healthcare for a combined 50 years.
The Company is initially focusing on
chronic costly GI conditions that have high mental health burden,
such as inflammatory bowel disease ("IBD") which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles
often experienced by individuals suffering from a variety of
chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.
The Trellus Elevate™ program
incorporates the GRITT™ methodology and learnings on resilience
from clinical research and practice conducted at the Mount Sinai
IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to
demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94%
reduction in unplanned hospitalisations, which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers and health systems. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information on Trellus Health, visit:
www.trellushealth.com
1 Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258